A great article from Healio featuring thoughts from Dr Joshua Goldberg and Dr Catalin Toma on the SPIRARE II trial and #Endoportal Control for the treatment of pulmonary embolism. https://lnkd.in/gCKB8ysJ *The Vertex Pulmonary Embolectomy System is for investigational use only.
Jupiter Endovascular
医疗设备制造业
Menlo Park，California 1,448 位关注者
Join our quest to reinvent endovascular medicine
关于我们
Imagine a world where you could bring the precision and control of surgery to catheter-based therapies. For decades, endovascular procedures have been constrained by the technological limitations of catheters that lose stability and control within the anatomy. We have created a new class of therapies to overcome these constraints by using Endoportal Control to mimic the precision and control of direct surgical access, while maintaining the minimally invasive profile of an endovascular intervention. Our vision is big, spanning the breadth of cardiovascular disease where we see compelling opportunities to reimagine therapies for millions of patients. Jupiter Endovascular is a medical technology startup located in the San Francisco Bay Area, led by a team of successful medical device entrepreneurs. We have big ambitions, with a culture built on innovation, teamwork, and speed. We have raised capital from a diversified investor base, including venture capital, private equity, corporate strategic investors, and clinician angel investors.
- 网站
-
jupiterendo.com
Jupiter Endovascular的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Menlo Park，California
- 类型
- 私人持股
地点
-
主要
获取路线
155 Jefferson Dr
Suite 100
US，California，Menlo Park，94025
Jupiter Endovascular员工
动态
-
The world's first-ever interventional procedure using #Endoportal Control was performed last week on September 10, 2024 by Krzysztof Bartus MD PhD, Grzegorz Kopec, and Jakub Stepniewski at the St. John Paul II Hospital in Krakow, Poland, where they used the Vertex Pulmonary Embolectomy System for the first time to successfully treat a patient with acute pulmonary embolism as part of the SPIRARE I clinical study. This marks a momentous milestone in our quest to revolutionize endovascular medicine. A big congratulations and thank-you to the SPIRARE I investigators for this monumental achievement! Read more: https://bit.ly/3XzlWoF *The Vertex Pulmonary Embolectomy System is for investigational use only.
-
-
Thanks to Bob Kronemyer at MD+DI for a great article on the power of Jupiter Endovascular’s Endoportal Control technology. The piece does a great job of explaining how our new technology works and its clinical potential to improve the safety and efficacy for all patients undergoing an endovascular procedure. It’s all about the patients!
Jupiter Endovascular Receives Clinical Trial Funding
mddionline.com
-
We’re thrilled to share that we’ve received FDA approval to begin the SPIRARE II pivotal trial, led by National Co-PIs Catalin Toma and Joshua Goldberg, to assess the use of #Endoportal Control for treating Pulmonary Embolism! More to come soon on the SPIRARE I clinical study as well. Join our quest to reinvent endovascular medicine. *The Vertex Pulmonary Embolectomy System is for investigational use only.
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control - Jupiter Endovascular
https://jupiterendo.com
-
We are excited to exit stealth mode and introduce Carl St. Bernard as our new CEO! Join our quest to reinvent endovascular medicine.
Jupiter Endovascular Exits Stealth with $21M in New Financing to Fund Pivotal Trial For Pulmonary Embolism - Jupiter Endovascular
https://jupiterendo.com